Literature DB >> 19479394

[Amiodarone-induced pulmonary toxicity].

A Heisel1, M Berg, M Stopp, D Ukena, H Schieffer.   

Abstract

Amiodarone is highly effective in suppressing ventricular and supraventricular tachyarrhythmias. The most serious adverse reaction is pulmonary toxicity. The mechanisms involved in amiodarone-induced pulmonary injury are incompletely understood. Several forms of pulmonary disease occur including interstitial pneumonitis, fibrosis or organizing pneumonia. The incidence is generally lower with lower maintenance doses (<or= 300 mg/d). There are no adequate predictors of pulmonary toxicity due to amiodarone. The diagnosis of amiodarone-induced pulmonary toxicity is one of exclusion. Treatment consists primarily of stopping amiodarone application. Corticosteroid therapy can be life-saving for severe cases and for patients in whom withdrawl of amiodarone is not possible.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 19479394     DOI: 10.1007/BF03041977

Source DB:  PubMed          Journal:  Med Klin (Munich)        ISSN: 0723-5003


  21 in total

Review 1.  Amiodarone pulmonary toxicity.

Authors:  W D Pitcher
Journal:  Am J Med Sci       Date:  1992-03       Impact factor: 2.378

2.  Respiratory disease induced by drugs.

Authors:  P Camus
Journal:  Eur Respir J       Date:  1997-02       Impact factor: 16.671

3.  Drugs that may injure the respiratory system.

Authors:  P Foucher; M Biour; J P Blayac; P Godard; C Sgro; M Kuhn; J M Vergnon; D Vervloet; P Pfitzenmeyer; M Ollagnier; C Mayaud; P Camus
Journal:  Eur Respir J       Date:  1997-02       Impact factor: 16.671

4.  Amiodarone pulmonary toxicity: CT findings in symptomatic patients.

Authors:  J E Kuhlman; C Teigen; H Ren; R H Hruban; G M Hutchins; E K Fishman; R H Hurban
Journal:  Radiology       Date:  1990-10       Impact factor: 11.105

5.  Possible association of pneumonitis with amiodarone therapy.

Authors:  H H Rotmensch; M Liron; M Tupilski; S Laniado
Journal:  Am Heart J       Date:  1980-09       Impact factor: 4.749

6.  Evaluation of reactive oxygen species involvement in amiodarone pulmonary toxicity in vivo and in vitro.

Authors:  R G Leeder; E Rafeiro; J F Brien; C C Mandin; T E Massey
Journal:  J Biochem Toxicol       Date:  1996

7.  Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators.

Authors:  J A Cairns; S J Connolly; R Roberts; M Gent
Journal:  Lancet       Date:  1997-03-08       Impact factor: 79.321

8.  Relationships between amiodarone dosage, drug concentrations, and adverse side effects.

Authors:  J J Heger; E N Prystowsky; D P Zipes
Journal:  Am Heart J       Date:  1983-10       Impact factor: 4.749

Review 9.  Amiodarone pulmonary toxicity. Recognition and pathogenesis (Part I).

Authors:  W J Martin; E C Rosenow
Journal:  Chest       Date:  1988-05       Impact factor: 9.410

10.  Relation between amiodarone and desethylamiodarone plasma concentrations and electrophysiologic effects, efficacy and toxicity.

Authors:  M L Greenberg; B B Lerman; J R Shipe; D L Kaiser; J P DiMarco
Journal:  J Am Coll Cardiol       Date:  1987-05       Impact factor: 24.094

View more
  1 in total

1.  [Drug-induced pulmonary diseases].

Authors:  D Ukena
Journal:  Pneumologe (Berl)       Date:  2007-04-26
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.